Co-Delivery Nanosystems for Cancer Treatment: A Review

Pharm Nanotechnol. 2019;7(2):90-112. doi: 10.2174/2211738507666190321112237.

Abstract

Massive data available on cancer therapy more than ever lead our mind to the general concept that there is no perfect treatment for cancer. Indeed, the biological complexity of this disease is too excessive to be treated by a single therapeutic approach. Current delivery systems containing a specific drug or gene have their particular opportunities and restrictions. It is worth noting that a considerable number of studies suggest that single- drug delivery systems result in insufficient suppression of cancer growth. Therefore, one of the main ideas of co-delivery system designing is to enhance the intended response or to achieve the synergistic/combined effect compared to the single drug strategy. This review focuses on various strategies for co-delivery of therapeutic agents in the treatment of cancer. The primary approaches within the script are categorized into co-delivery of conventional chemotherapeutics, gene-based molecules, and plant-derived materials. Each one is explained in examples with the recent researches. In the end, a brief summary is provided to conclude the gist of the review.

Keywords: Anti-cancer materials; cancer therapy; co-delivery; drug-drug; drug-gene; gene-gene; therapeutic agents..

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Combined Modality Therapy / methods
  • Drug Synergism
  • Genetic Therapy / methods
  • Humans
  • Molecular Targeted Therapy / methods
  • Nanocapsules / chemistry*

Substances

  • Antineoplastic Agents
  • Nanocapsules